Treatment Failure Down With Standard-Course Therapy in Pediatric UTI
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
MONDAY, July 3, 2023 -- For children with urinary tract infection (UTI), standard-course therapy is associated with lower rates of treatment failure, according to a study published online June 26 in JAMA Pediatrics.
Theoklis Zaoutis, M.D., from the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, and colleagues compared the efficacy of standard-course and short-course therapy for children with UTI in a randomized clinical noninferiority trial. Data were included for 664 children aged 2 months to 10 years with UTI exhibiting clinical improvement after five days of antimicrobials who were randomly assigned to another five days of antimicrobials (standard-course therapy) or five days of placebo (short-course therapy; 328 and 336 children, respectively).
The researchers found that 0.6 and 4.2 percent of those assigned to standard-course and short-course therapy had treatment failure, defined as symptomatic UTI at or before the first follow-up visit (days 11 to 14; absolute difference, 3.6 percent; upper bound of 95 percent confidence interval, 5.5 percent). The likelihood of having asymptomatic bacteriuria or a positive urine culture at or by the first follow-up visit was increased for children receiving short-course therapy. No between-group differences were seen in the rates of UTI after the first follow-up visit, incidence of adverse events, or incidence of gastrointestinal colonization with resistant organisms.
"The slightly increased risk of treatment failure with the added benefit of convenience and potentially less adverse events should be discussed with parents; in this way, they can contribute to conversations surrounding the ultimate duration of therapy prescribed," write the authors of an accompanying editorial.
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2023
Read this next
Biomarkers + Patient-Reported Outcomes Up Prediction of Interstitial Cystitis
TUESDAY, May 7, 2024 -- The integration of biomarkers and patient-reported outcomes (PROs) improves prediction of interstitial cystitis (IC)/bladder pain syndrome, according to a...
FDA Approves New Antibiotic, Pivya, for Uncomplicated Urinary Tract Infections
TUESDAY, April 30, 2024 -- The U.S. Food and Drug Administration has approved Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary tract...
Computer Prompts Could Reduce Empiric Antibiotic Use for UTI
FRIDAY, April 19, 2024 -- For non-critically ill patients with urinary tract infection (UTI), computerized provider order entry (CPOE) prompts providing patient- and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.